Seer Inc. Balances Growth Momentum With Cautious Outlook

Seer, Inc. ((SEER)) has held its Q4 earnings call. Read on for the main highlights of the call.

Seer’s latest earnings call painted a mixed but constructive picture for investors. Management highlighted strong commercial traction, rapid adoption of its Proteograph platform and expanding scientific validation, yet balanced this with cautious commentary on funding headwinds, modest near‑term growth and ongoing sizeable losses as the company scales.

Full-Year Revenue Growth Signals Early Commercial Progress

Seer reported 2025 revenue of $16.6 million, up 17% from 2024, showing that demand for its proteomics platform is building. Excluding related party revenue, growth was roughly 33% year over year, underscoring healthier underlying momentum as the business transitions toward a more diversified customer base.

Quarterly Revenue and Product Mix Show Moderate Momentum

Fourth-quarter 2025 revenue came in at $4.2 million, a 5% increase versus Q4 2024 and roughly 16% growth excluding related party sales. Product revenue reached $2.8 million while services contributed $1.2 million, reflecting a steady mix as customers ramp usage of instruments and consumables.

Installed Base Expansion Accelerates Platform Adoption

The installed base climbed to 82 instruments at year-end 2025, a 67% jump from 49 systems a year earlier. Around 60% of 2025 placements came through the Strategic Instrument Placement Program, showing Seer’s willingness to seed the market and build long-term relationships despite near-term capital constraints.

Consumable Growth Highlights Increasing Utilization

Consumable kit volume rose approximately 69% year over year, indicating customers are running more samples on the Proteograph platform. Management estimated consumable pull-through at about $113,000 per instrument, while noting methodology caveats and a temporary dip as many newly installed systems are still ramping.

Scientific Validation and Publications Strengthen Credibility

Peer-reviewed publications nearly doubled to 70 by the end of 2025, up from 36 a year prior, including notable work in Nature and Nature Genetics. Multiple presentations at major conferences further reinforced Seer’s scientific standing, which is crucial for driving long-term adoption in the research community.

Customer Launch Underscores Commercial Potential

A key commercial milestone came when customer PrognomIQ launched ProVue Lung, a proteomics-based test for early lung cancer detection. Seer, which holds a minority stake in PrognomIQ, sees this as a proof point that its technology can underpin real-world diagnostic products and create strategic upside beyond system sales.

Product and R&D Advances Boost Throughput and Roadmap

In June 2025, Seer introduced the Proteograph ONE assay and SP200 automation instrument, raising throughput to more than 1,000 samples per week versus 112 in 2021. The roadmap calls for PAS v4 with an AI-enabled interface in 2026 and a proteoform profiling assay in 2027, targeting higher productivity and richer biological insights.

Cost Discipline and Cash Position Extend Runway

Operating expenses fell 19% year over year to $86.5 million, while net loss narrowed to $73.6 million from $86.6 million, showing better financial discipline. Free cash flow loss improved to about $45.6 million, and the company ended 2025 with roughly $241 million in cash and investments, providing a sizable cushion.

Share Repurchases Reflect Capital Allocation Confidence

Seer repurchased approximately 5.3 million Class A shares in 2025 for about $10.2 million, bringing total buybacks to 11.7 million shares since inception. With shares outstanding reduced by around 13% and a fresh $25 million repurchase authorization, management signaled confidence in the company’s long-term value.

Large-Scale Study Wins Highlight Platform Scalability

The Proteograph platform was selected for several population-scale projects, including a 20,000-sample study with Korea University and a 10,000-sample effort with Discovery Life Sciences. These wins demonstrate that Seer’s technology can handle large cohorts, potentially translating into meaningful consumable demand over time.

Q4 Shortfall Tied to Funding Delays and NIH Pressure

Despite overall growth, fourth-quarter results fell short of internal expectations as customer budgets tightened and NIH-related payments slipped into 2026. Management pointed to deferred purchases and delayed project funding as key drivers, reinforcing how sensitive demand remains to public and academic funding cycles.

Conservative 2026 Outlook Reflects Funding Uncertainty

For 2026, Seer guided revenue to $16 million–$18 million, implying only about 3% growth at the midpoint versus 2025. The outlook assumes continued pressure on instrument placements and customer budgets and deliberately excludes upside from potential new large-scale study awards, emphasizing prudence over optimism.

Persistent Losses Underscore Scaling Challenge

Even with improvement, Seer’s 2025 net loss of $73.6 million and operating expenses of $86.5 million underscore the high cost of scaling a platform business. Management stressed that investments in R&D, commercial infrastructure and support are necessary to capture the long-term proteomics opportunity, but they weigh heavily on near-term profitability.

Reliance on External Funding Creates Volatility

Seer’s sales cycles remain elongated as customer capital budgets face pressure and NIH and other government funding remain uncertain. A small number of large population studies can move revenue significantly from quarter to quarter, making results lumpy and adding forecasting risk for investors.

Forward-Looking Guidance Emphasizes Caution and Runway

Management expects 2026 revenue of $16–18 million, modestly above 2025, while aiming to further reduce free cash flow losses as cost discipline continues. They believe the roughly $241 million cash balance and sizable tax assets are sufficient to reach cash-flow breakeven over time, and reiterated a long-term gross margin target of 70–75% alongside ongoing share repurchases.

Seer’s earnings call portrayed a company with clear technological momentum and growing scientific adoption but constrained by a tough funding backdrop and ongoing losses. For investors, the story remains one of long-term optionality in proteomics with near-term results subject to funding cycles, large-deal timing and management’s ability to keep tightening the financial screws.